Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arterial perfusion bevacizumab combined with TACE for advanced biliary tract tumors
ChiCTR-IPR-15007069Phase 3Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of bevacizumab in biliary cancer (2 arms), sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Primary endpoint: Progression-free survival. Planned start Mar 2016; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR-IPR-15007069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15007069.